Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach.

Patel NM, Jo H, Eberhard DA, Yin X, Hayward MC, Stein MK, Hayes DN, Grilley-Olson JE.

Appl Immunohistochem Mol Morphol. 2018 Aug 10. doi: 10.1097/PAI.0000000000000684. [Epub ahead of print]

PMID:
30102605
2.

Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors.

Busch EL, Don PK, Chu H, Richardson DB, Keku TO, Eberhard DA, Avery CL, Sandler RS.

BMC Cancer. 2018 Jan 16;18(1):82. doi: 10.1186/s12885-017-3964-3.

3.

Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.

Patel NM, Michelini VV, Snell JM, Balu S, Hoyle AP, Parker JS, Hayward MC, Eberhard DA, Salazar AH, McNeillie P, Xu J, Huettner CS, Koyama T, Utro F, Rhrissorrakrai K, Norel R, Bilal E, Royyuru A, Parida L, Earp HS, Grilley-Olson JE, Hayes DN, Harvey SJ, Sharpless NE, Kim WY.

Oncologist. 2018 Feb;23(2):179-185. doi: 10.1634/theoncologist.2017-0170. Epub 2017 Nov 20.

4.

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri FJ, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Lih CJ, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID.

Clin Cancer Res. 2017 Aug 1;23(15):4127-4137. doi: 10.1158/1078-0432.CCR-16-2818. Epub 2017 Apr 5.

5.

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Grossman RL, Abel B, Angiuoli S, Barrett JC, Bassett D, Bramlett K, Blumenthal GM, Carlsson A, Cortese R, DiGiovanna J, Davis-Dusenbery B, Dittamore R, Eberhard DA, Febbo P, Fitzsimons M, Flamig Z, Godsey J, Goswami J, Gruen A, Ortuño F, Han J, Hayes D, Hicks J, Holloway D, Hovelson D, Johnson J, Juhl H, Kalamegham R, Kamal R, Kang Q, Kelloff GJ, Klozenbuecher M, Kolatkar A, Kuhn P, Langone K, Leary R, Loverso P, Manmathan H, Martin AM, Martini J, Miller D, Mitchell M, Morgan T, Mulpuri R, Nguyen T, Otto G, Pathak A, Peters E, Philip R, Posadas E, Reese D, Reese MG, Robinson D, Dei Rossi A, Sakul H, Schageman J, Singh S, Scher HI, Schmitt K, Silvestro A, Simmons J, Simmons T, Sislow J, Talasaz A, Tang P, Tewari M, Tomlins S, Toukhy H, Tseng HR, Tuck M, Tzou A, Vinson J, Wang Y, Wells W, Welsh A, Wilbanks J, Wolf J, Young L, Lee J, Leiman LC.

Clin Pharmacol Ther. 2017 May;101(5):589-592. doi: 10.1002/cpt.666. Epub 2017 Apr 12. Review.

6.

The molecular basis of breast cancer pathological phenotypes.

Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman FM, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen GM, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH.

J Pathol. 2017 Feb;241(3):375-391. doi: 10.1002/path.4847. Epub 2016 Dec 29.

7.

Evaluating markers of epithelial-mesenchymal transition to identify cancer patients at risk for metastatic disease.

Busch EL, Keku TO, Richardson DB, Cohen SM, Eberhard DA, Avery CL, Sandler RS.

Clin Exp Metastasis. 2016 Jan;33(1):53-62. doi: 10.1007/s10585-015-9757-7. Epub 2015 Oct 27.

8.

Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing.

Montgomery ND, Parker JS, Eberhard DA, Patel NM, Weck KE, Sharpless NE, Hu Z, Hayes DN, Gulley ML.

Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):490-5. doi: 10.1097/PAI.0000000000000215.

9.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.

Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, Salazar AH, Jo H, Soloway MG, Wilkerson MD, Parker JS, Yin X, Zhang G, Siegel MB, Rosson GB, Earp HS 3rd, Sharpless NE, Gulley ML, Weck KE, Hayes DN, Moschos SJ.

PLoS One. 2015 Jun 15;10(6):e0129280. doi: 10.1371/journal.pone.0129280. eCollection 2015.

10.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE.

Pigment Cell Melanoma Res. 2014 Jul;27(4):653-63. doi: 10.1111/pcmr.12238. Epub 2014 Apr 7.

11.

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

BMC Med. 2013 Oct 17;11:220. doi: 10.1186/1741-7015-11-220.

12.

Criteria for the use of omics-based predictors in clinical trials.

McShane LM, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, Williams PM, Mesirov JP, Polley MY, Kim KY, Tricoli JV, Taylor JM, Shuman DJ, Simon RM, Doroshow JH, Conley BA.

Nature. 2013 Oct 17;502(7471):317-20. doi: 10.1038/nature12564.

13.

Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer.

Potts SJ, Huff SE, Lange H, Zakharov V, Eberhard DA, Krueger JS, Hicks DG, Young GD, Johnson T, Whitney-Miller CL.

Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):21-30. doi: 10.1097/PAI.0b013e31825552a3.

PMID:
22820657
14.

Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue.

Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, Schmechel SC, Lange H.

Lab Invest. 2012 Sep;92(9):1342-57. doi: 10.1038/labinvest.2012.91. Epub 2012 Jul 16.

15.

Diverse somatic mutation patterns and pathway alterations in human cancers.

Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S.

Nature. 2010 Aug 12;466(7308):869-73. doi: 10.1038/nature09208. Epub 2010 Jul 28.

PMID:
20668451
16.

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.

Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, Cappuzzo F.

J Clin Pathol. 2009 Nov;62(11):970-7. doi: 10.1136/jcp.2009.066548.

17.

A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.

Boyd ZS, Raja R, Johnson S, Eberhard DA, Lackner MR.

J Mol Diagn. 2009 Jul;11(4):290-7. doi: 10.2353/jmoldx.2009.080124. Epub 2009 May 21.

18.

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

Eberhard DA, Giaccone G, Johnson BE; Non-Small-Cell Lung Cancer Working Group.

J Clin Oncol. 2008 Feb 20;26(6):983-94. doi: 10.1200/JCO.2007.12.9858. Review.

PMID:
18281673
19.

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE.

Clin Cancer Res. 2007 Oct 15;13(20):6175-81.

20.

Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection.

Peters BA, Kan Z, Sebisanovic D, Pujara K, Wang Z, Hong P, Chow B, Stinson J, Carlton VE, Pham TQ, Stern H, Waring P, Hillan KJ, Eberhard DA, de Sauvage F, Zheng J, Faham M, Seshagiri S.

Nat Methods. 2007 Sep;4(9):713-5. Epub 2007 Aug 19.

PMID:
17704782
21.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.

J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
16896006
22.

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.

23.

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.

J Clin Oncol. 2005 Sep 1;23(25):5900-9. Epub 2005 Jul 25.

PMID:
16043828
24.

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D.

J Natl Cancer Inst. 2005 Jun 15;97(12):880-7.

PMID:
15956649
25.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A.

J Clin Oncol. 2005 Apr 10;23(11):2544-55. Epub 2005 Mar 7.

PMID:
15753462
26.

GEPIS--quantitative gene expression profiling in normal and cancer tissues.

Zhang Y, Eberhard DA, Frantz GD, Dowd P, Wu TD, Zhou Y, Watanabe C, Luoh SM, Polakis P, Hillan KJ, Wood WI, Zhang Z.

Bioinformatics. 2004 Oct 12;20(15):2390-8. Epub 2004 Apr 8.

PMID:
15073007
27.

Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction.

Jin H, Yang R, Li W, Ogasawara AK, Schwall R, Eberhard DA, Zheng Z, Kahn D, Paoni NF.

J Pharmacol Exp Ther. 2003 Feb;304(2):654-60.

PMID:
12538818
28.

Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding.

Eberhard DA, Karns LR, VandenBerg SR, Creutz CE.

J Cell Sci. 2001 Sep;114(Pt 17):3155-66.

29.

Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid.

Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D.

Cancer Res. 2001 May 15;61(10):4197-205.

30.
31.

Annexins I and II bind to lipid A: a possible role in the inhibition of endotoxins.

Eberhard DA, Vandenberg SR.

Biochem J. 1998 Feb 15;330 ( Pt 1):67-72.

32.

Histopathology of arteriovenous malformations after gamma knife radiosurgery.

Schneider BF, Eberhard DA, Steiner LE.

J Neurosurg. 1997 Sep;87(3):352-7.

PMID:
9285598
34.

Alzheimer's disease in a case of cortical basal ganglionic degeneration with severe dementia.

Eberhard DA, Lopes MB, Trugman JM, Brashear HR.

J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):109-10. No abstract available.

36.

Two-year-old boy with Proteus syndrome and fatal pulmonary thromboembolism.

Eberhard DA.

Pediatr Pathol. 1994 Sep-Oct;14(5):771-9.

PMID:
7808975
37.

Pleomorphic xanthoastrocytoma, a distinctive astroglial tumor: neuroradiologic and pathologic features.

Lipper MH, Eberhard DA, Phillips CD, Vezina LG, Cail WS.

AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1397-404.

PMID:
8279337
39.
41.

MgATP-independent and MgATP-dependent exocytosis. Evidence that MgATP primes adrenal chromaffin cells to undergo exocytosis.

Holz RW, Bittner MA, Peppers SC, Senter RA, Eberhard DA.

J Biol Chem. 1989 Apr 5;264(10):5412-9.

42.

Intracellular Ca2+ activates phospholipase C.

Eberhard DA, Holz RW.

Trends Neurosci. 1988 Dec;11(12):517-20. No abstract available.

Supplemental Content

Loading ...
Support Center